Please be advised that Diagnostic Solutions Laboratory has implemented a slight price increase on select tests. These updated prices are now reflected in our test menu. We encourage you to review the revised pricing prior to placing any new orders. As always, we sincerely appreciate your continued partnership and business.
ClientID: 0
Session Timeout Alert
Your Login Session is about to expire due to inactivity.
UPDATE: MARCH 20, 2020 - 12:00 P.M.
LabCorp PSCs in California will remain open despite yesterday’s ‘Stay at Home Order’. In addition, LabCorp will have 3 labs online performing COVID-19 testing by the end of today with the ability to handle 20,000 tests per day. This should reduce the current turnaround time, along with the Roche and Thermo Fisher technology being employed. There is currently a shortage of COVID-19 collection supplies, but this shortage is expected to be short term.
UPDATE: MARCH 19, 2020 - 5:00 P.M.
Media Statement: LabCorp Announces Ability to Perform 20,000 Tests Per Day, Doubles Its COVID-19 Testing Capacity in One Week
LabCorp announced that it will be able to perform more than 20,000 COVID-19 tests per day beginning Friday, March 20, ahead of its original schedule. This represents a significant increase in capacity since the company released its COVID-19 test two weeks ago. The company is working continuously to increase capacity and support the needs of healthcare workers, patients, government, clients and other organizations, and expects capacity to continue to increase.
The company is intently focused on making COVID-19 laboratory testing available to patients who are symptomatic and should be tested. LabCorp has moved quickly to significantly increase its testing capacity by adding staff, equipment and more high-throughput testing now underway as a result of approved emergency use authorization (EUAs). LabCorp is now performing COVID-19 testing at its labs in Phoenix, Ariz., Burlington, N.C., and Raritan, N.J.
As a reminder, LabCorp does not collect specimens for the test. Patients for whom testing has been ordered should not be sent to LabCorp location to have a specimen collected. Instead, an appropriate specimen must be collected at the healthcare facility where the patient was seen and the test was ordered. The specimen should be sent to the companies using standard procedures. Test results will be available in 3-4 days from the pickup of the specimen to release of the test result.
If you believe you have been exposed to Coronavirus (COVID-19), please do not enter a patient service center. Immediately contact your physician or healthcare provider. Testing must be collected by a physician or an authorized healthcare provider. LabCorp employees are not able to collect the specimens in LabCorp patient service centers.
To ensure the health of our patients, employees and the broader community, please follow these guidelines.
1. We request the first business hour each day is set aside to serve people who are 65 or older and those with serious underlying medical conditions.
2. We’ve launched the “Wait Where You’re Comfortable” Program. Once checked in, you can wait in your vehicle or other nearby location. If you make an appointment online and provide your cell phone number, check in from your mobile device and we will text you when we’re ready to see you.
UPDATE: MARCH 18, 2020 - 11:30 A.M.
LabCorp is proud of the work that we, along with our industry partners, are doing to quickly mobilize the United States to get back on its feet by bringing access to nationwide testing for COVID-19. We continue to work closely with federal and state authorities and health officials, as well as other key constituencies to make testing available for patients who should be tested and increase test capacity in response to this public health crisis.
LabCorp does not collect specimens for COVID-19 testing at our locations, and we are asking individuals who are or may be positive for COVID-19 not to visit our locations to help minimize possible transmission. LabCorp’s patient service centers and other locations follow strict personal and environmental hygiene protocols, which have been further strengthened and reinforced with all employees since the early days of the COVID-19 outbreak. But all available evidence is that people can be contagious before exhibiting any symptoms, and without knowing that they have been exposed or may be infected.
As we learn of employees who may have been exposed, we are moving quickly to make sure they are following all recommendations and protocols, including self-quarantine, and receive appropriate care and support. We are also working in coordination with public health authorities to respond when we are informed about visitors to our locations who may have been infected and could have exposed others. If we learn of a potential exposure, the location will be closed and thoroughly cleaned so that we can bring it back online to serve patients and their healthcare needs.
The health and safety of our employees, the public, patients and healthcare service providers is of the utmost importance. We are committed to working with the relevant governmental and healthcare authorities in response to COVID-19 and ensuring that we are communicating key developments as they occur.
LabCorp and our dedicated employees are intensely focused on performing testing for COVID-19 and increasing capacity to make testing available for patients who should be tested. We are deeply proud of everything our colleagues have done to respond to this unprecedented crisis, and all that they will continue to do.
Coronavirus testing is now available for Evexia clients nationwide through LabCorp. The LabCorp 2019 Novel Coronavirus (COVID-19) test requires specimens collected from the nose, throat or lungs, which must be collected by an appropriate licensed healthcare provider. The preferred sample types are nasopharyngeal (NP) or oropharyngeal (OP) swabs. Other appropriate sample types are NP or OP aspirates or washes, and bronchoalvelaor lavage (BAL).
“As COVID-19 continues to spread in the U.S., having high-quality, reliable, scalable laboratory tests available is a critically important part of the response,” said Marcia Eisenberg, Ph.D., chief scientific officer for LabCorp Diagnostics. “Identifying people who are infected is necessary to make sure that patients receive the appropriate care, to better manage the use of healthcare resources, and to help contain the spread of the virus. We will continue to stay closely involved in the ongoing response, and we are prepared to expand our testing capacity to help meet demand.”
CDC guidance on the clinical and epidemiological criteria for COVID-19 infection risk is available here
More information about LabCorp’s response to COVID-19 is available at https://www.labcorp.com/information-labcorp-about-coronavirus-disease-2019-covid-19.
Individuals seeking testing for COVID-19 should not visit a LabCorp location to request a test. Tests must be ordered by a physician or other authorized healthcare provider.
LabCorp does not currently collect specimens for COVID-19 testing. Patients for whom testing has been ordered should not be sent to a LabCorp location to have a specimen collected.
Click the button below to order the test for a patient or contact us for additional information & ordering 888-852-2723
You are attempting to learn about a feature that is not available to an EvexiaLite account status. To gain access to this feature please click the button below to upgrade to an EvexiaComplete account where you will have access to:
Unbeatable pricing on Diagnostic Testing
Access to over 6000 Conventional and Specialty tests
EvexiaDirect - Patients pay directly for orders you assign.
Client bill - You pay Evexia and then set your own patient pricing
Access to our Custom Panel Creator
EMR/ EHR Integration
Access to Thousands of Patient Service Centers
Extended client hours 8 am - 8 pm, 5 days a week. Email support for urgent matters on weekend and holidays.